Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023

Publisher Name :
Date: 01-Apr-2017
No. of pages: 85
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Chemotherapy Induced Nausea and Vomiting (CINV)- Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023.

Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can't get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn't be physically string to bear the chemotherapy side-effects.

According to DelveInsight, the global market for Chemotherapy Induced Nausea and Vomiting (CINV) is estimated to be USD XX Million by 2023 at a CAGR of 8.32 % for the forecast period i.e., 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.

Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Nausea and Vomiting (CINV) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

To understand the future market competition in the 7MM market of Chemotherapy Induced Nausea and Vomiting (CINV) and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

The Report also covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV)market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023

Table of Contents

Report Introduction
Chemotherapy Induced Nausea and Vomiting (CINV) Market Overview at a Glance
Global Market Size of CINV in 2016
Global Market Size of CINV in 2023
Chemotherapy Induced Nausea and Vomiting (CINV)
Overview
Types of CINV
Risk Factors
Pathophysiology of CINV
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States
Europe
Germany
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany
Italy
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy
Spain
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain
France
Incident Cases of Chemotherapy Induced Nausea and Vomiting in France
United Kingdom
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom
Japan
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan
Treatment Algorithm
Emetic Risk Category of Chemotherapeutic Agents
Emetogenic potential of Intravenous anti-neoplastic agents
Emetogenic potential of oral anti-neoplastic agents
NHS Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV)
Summary of Anti-emetics prescribing
First line Anti-emetics
Second Line Anti-emetics
Standard Anti-Emetic Regimes for Haematology Oncology
MASCC/ESMO Antiemetic Guideline 2016
Acute Chemotherapy Induced Nausea and Vomiting Guidelines
Delayed Chemotherapy Induced Nausea and Vomiting Guidelines
Guidelines for Other types of CINV cases
Guidelines for CINV in Children
ASCO Guidelines for treatment of CINV
NCCN Guidelines for Chemotherapy Induced Nausea and Vomiting
High emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Moderate emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Low and minimal emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Oral chemotherapy- emesis prevention
Breakthrough treatment for CINV
Anticipatory Emesis Prevention/treatment
Marketed Drugs
List of Marketed Drugs
Generic Drugs and their Efficacy
Marketed Drugs Presence
Sustol: Heron Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sustol
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sancuso
Product Profile
Aloxi: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Aloxi
Product Profile
Akynzeo: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Akynzeo
Product Profile
Emend: Merck Sharp and Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Emend
Product Profile
Varubi: Tesaro, Inc.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Varubi
Product Profile
Ivemend: Merck Sharp & Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Ivemend
Product Profile
Kytril: Hoffmann-La Roche
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Kytril
Product Profile
Syndros: Insys Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Syndros
Product Profile
Other Approved Drugs for Chemotherapy induced Nausea and Vomiting (CINV)
Zofran: Novartis
Zuplenz: Par Pharmaceutical, Inc.
Emerging Therapies
Pipeline Drugs
Pipeline Drugs Results
Cinvanti: Heron Therapeutics, Inc.
Clinical Development
Advantages & Disadvantages
Product Profile
Akynzeo(IV): Helsinn Birex Pharmaceuticals Ltd.
Advantages & Disadvantages
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Advantages & Disadvantages
Product Profile
Rolapitant(IV): Tesaro, Inc.
Drug Description
Advantages & Disadvantages
Product Profile
Market Size
Assumptions and Caveats
Forecasting Events
Global CINV: Country-Wise Market Analysis
United States
Europe
Japan
Market Drivers
Market Barriers
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight


List of Tables

Table 1: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States (2013-2023)
Table 2: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany (2013-2023)
Table 3: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy (2013-2023)
Table 4: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain (2013-2023)
Table 5: Incident Cases of Chemotherapy Induced Nausea and Vomiting in France (2013-2023)
Table 6: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom (2013-2023)
Table 7: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan (2013-2023)
Table 8: List of Marketed Drugs for Chemotherapy Induced Nausea and Vomiting
Table 9: Generic Drugs and their Efficacy for Chemotherapy Induced Nausea and Vomiting
Table 10: Marketed Drugs Presence for Chemotherapy Induced Nausea and Vomiting
Table 11: List of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 12: Results of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 13: Global Market Size of CINV in USD, Million (2013-2023)
Table 14: United States Market Size of CINV in USD, Million (2013-2023)
Table 15: Europe Market Size of CINV in USD, Million (2013-2023)
Table 16:JapanMarket Size of CINV in USD, Million (2013-2023)


List of Figures

Figure 1: Emetic Pathways involved in Nausea and Vomiting
Figure 2: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States (2013-2023)
Figure 3: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany (2013-2023)
Figure 4: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy (2013-2023)
Figure 5: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain (2013-2023)
Figure 6: Incident Cases of Chemotherapy Induced Nausea and Vomiting in France (2013-2023)
Figure 7: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom (2013-2023)
Figure 8: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan (2013-2023)
Figure 9: Emetogenic potential of Intravenous anti-neoplastic agents
Figure 10: Emetogenic potential of oral anti-neoplastic agents
Figure 11: Summary of anti-emetic prescribing (in normal renal / hepatic function)
Figure 12: Summary of anti-emetic prescribing (in normal renal / hepatic function)
Figure 13: First Line Anti-Emetics
Figure 14: Second Line Anti-emetics
Figure 15: Standard Anti-Emetic Regimes For Haematology Oncology
Figure 16: Acute Nausea and Vomiting anti-emetics guideline overview
Figure 17: Delayed Nausea and Vomiting anti-emetics guideline overview
Figure 18: Delayed Nausea and Vomiting anti-emetics guideline overview
Figure 19: High emetic risk, Intravenous chemotherapy- acute and delayed emesis prevention
Figure 20: Moderate emetic risk, Intravenous chemotherapy- acute and delayed emesis prevention
Figure 21: Low and minimal emetic risk, Intravenous chemotherapy- emesis prevention
Figure 22: Oral chemotherapy- emesis prevention
Figure 23: Breakthrough treatment for CINV
Figure 24: Anticipatory Emesis Prevention/Treatment
Figure 25: Global Market Size of CINV in USD, Million (2013-2023)
Figure 26: United States Market Size of CINV in USD, Million (2013-2023)
Figure 27: Europe Market Size of CINV in USD, Million (2013-2023)
Figure 28:Japan Market Size of CINV in USD, Million (2013-2023)
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes
    Published: 11-Apr-2017        Price: US 2495 Onwards        Pages: 214
    Overview This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. In that report, we focused on the major classes of cancer immunotherapy drugs that were then emerging from academic and corporate research: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies. This new report includes an updated discussion of approved and clinical stage agents in......
  • Chemotherapy Induced Nausea and Vomiting (CINV) - Epidemiology Insights - 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 30
    DelveInsight's "Chemotherapy Induced Nausea and Vomiting (CINV)- Epidemiology Insights-2023" Report provides an overview of the disease, historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023 for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomf......
  • Colorectal cancer - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Apr-2017        Price: US 4950 Onwards        Pages: 115
    DelveInsight's "Colorectal cancer - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market size of the Colorectal Cancer (CRC) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed cases of Colorectal Cancer (CRC) from 2013-2023. According to DelveInsight, the 7MM Diagnosed cases for Colorectal Cancer are expected to increase,......
  • Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast -2023-7MM
    Published: 01-Apr-2017        Price: US 4950 Onwards        Pages: 87
    DelveInsight's "Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023-7MM" Reports provides an overview of the disease and global market size of the Non-Hodgkin Lymphoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the diagnosed cases of Non-Hodgkin Lymphoma from 2012-2023. Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. ......
  • B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 152
    B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape. B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms ......
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 418
    Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of th......
  • Polycythemia Vera - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 68
    Polycythemia Vera - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive ......
  • Osteosarcoma - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 255
    Osteosarcoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, sw......
  • Anal Cancer - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 183
    Anal Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs